CHM.CN Waverunner Capital (CNQ) rises 900% to C$0.05 on 11 Feb 2026: monitor liquidity and fundamentals

CHM.CN stock jumped 900.00% to C$0.05 in market hours on 11 Feb 2026, driven by heavy intraday trading relative to its average volume. The move lifted market cap to roughly C$37,211,650.00 and followed a prior close of C$0.01. Traders should note the share count of 744,233,000.00 and thin public liquidity, with a 50-day average price of C$0.04. This article examines drivers, fundamentals, sector context and short-term scenarios for Waverunner Capital Inc. (CHM.CN) on the CNQ exchange

Intraday move and trading context for CHM.CN stock

Today’s main fact is the price surge: CHM.CN stock increased by 900.00% to C$0.05 from a previous close of C$0.01. The jump followed unusually active trading versus the 50-day average price of C$0.04 and an average volume near 28,908.00 shares. There is no concurrent, clear regulatory filing or new earnings release explaining the spike, so volatility may reflect speculative flows or block trades rather than fresh fundamentals

CHM.CN stock fundamentals snapshot

Waverunner Capital Inc. (CHM.CN) reports an EPS of -0.01 and a trailing PE ratio of -5.00, reflecting losses. Market capitalization is approximately C$37,211,650.00 on CNQ in Canada with 744,233,000.00 shares outstanding. Book value per share is negative at -0.11 and cash per share is 0.01, indicating a thin balance sheet and limited liquidity cushion.

Technical setup and liquidity risks

Short-term technicals show the stock trading above its 50-day average price of C$0.04 and slightly above the 200-day average of C$0.05, increasing short-term volatility. Average daily volume is low at 28,908.00 shares, which raises spread and execution risk for positions larger than a few thousand dollars. For active traders, tight position sizing and limit orders are prudent.

Healthcare sector context and CHM.CN stock implications

Waverunner Capital is classified in the Healthcare sector and Drug Manufacturers – Specialty & Generic industry. The Canadian healthcare sector has underperformed recently (1-day -8.84%, YTD -2.81%), which raises headwinds for small-cap healthcare names. CHM.CN’s VC/venture exposures to renewables and biotech mean stock moves may be less correlated with large-cap drug makers and more sensitive to financing news and early-stage valuations.

Meyka AI grade and model forecast for CHM.CN stock

Meyka AI rates CHM.CN with a score out of 100: 64.99 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly figure of C$0.00, implying an expected downside versus the current C$0.05; forecasts are model-based projections and not guarantees. Use the grade as context, not a buy or sell recommendation.

Scenarios, price targets and trading strategy

Scenario-based price targets: a conservative near-term target of C$0.06 (20.00% above today’s price), a base-case target of C$0.10 (100.00% above today), and a high-risk speculative target of C$0.20 for event-driven upside. Given negative earnings and thin liquidity, a trade strategy should size risk carefully, use stop limits, and consider that model-based forecasts and grades are not guarantees. For filings and direct disclosures, check the company site: Waverunner Capital and reference market data at FinancialModelingPrep.

Final Thoughts

Key takeaways for CHM.CN stock: the intraday 900.00% jump to C$0.05 on 11 Feb 2026 highlights extreme short-term volatility and thin liquidity on the CNQ exchange. Fundamentals remain weak: EPS -0.01, negative book value per share and limited cash per share constrain a durable recovery absent new financing or material asset sales. Meyka AI rates the stock 64.99 (B, HOLD) and flags low liquidity and sector headwinds. Meyka AI’s forecast model projects C$0.00 on a yearly horizon, a model-based output that implies downside versus the current price; forecasts are not guarantees and should not be taken as investment advice. Traders looking for opportunity should treat CHM.CN as speculative, size positions small, apply strict risk limits, and watch for regulatory filings or financing announcements that could validate the current repricing. Use the price targets outlined—C$0.06 conservative, C$0.10 base, C$0.20 speculative—to shape trade plans, and combine those scenario targets with real-time news monitoring from official filings and company updates. Meyka AI provides this AI-powered market analysis as context for further research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.